{
    "id": 411,
    "fullName": "FGFR4 G388R",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR4 G388R lies within the transmembrane domain of the Fgfr4 protein (UniProt.org). G388R confers a gain of function to the Fgfr4 protein resulting in increased receptor stability, sustained receptor activation, increased ERK signaling and Stat3 phosphorylation, and promotes tumor formation in xenografts (PMID: 21622724, PMID: 22986737).",
            "references": [
                {
                    "id": 18,
                    "pubMedId": 21622724,
                    "title": "FGFR-4 Arg\u00b3\u2078\u2078 enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21622724"
                },
                {
                    "id": 444,
                    "pubMedId": 22986737,
                    "title": "The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22986737"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2264,
        "geneSymbol": "FGFR4",
        "terms": [
            "FGFR4",
            "CD334",
            "JTK2",
            "TKF"
        ]
    },
    "variant": "G388R",
    "createDate": "04/21/2014",
    "updateDate": "03/21/2019",
    "referenceTranscriptCoordinates": {
        "id": 164518,
        "transcript": "NM_213647",
        "gDna": "chr5:g.177093242G>A",
        "cDna": "c.1162G>A",
        "protein": "p.G388R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 725,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with pancreatic neuroendocrine tumors homozygous for FGFR4 G388 demonstrated increased tumor reduction following Afinitor (everolimus) treatment compared to patients harboring FGFR4 G388R (25% vs. 9%; p=0.049), however, partial response rate did not differ significantly due to small sample size (PMID: 22986737).",
            "molecularProfile": {
                "id": 541,
                "profileName": "FGFR4 G388R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1799,
                "name": "islet cell tumor",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 444,
                    "pubMedId": 22986737,
                    "title": "The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22986737"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7292,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, an FGFR4 G388R genotype was correlated with increased progression-free survival and overall survival and increased sensitivity to platinum-based therapy in ovarian cancer patients with no postoperative residual tumor (PMID: 22034009).",
            "molecularProfile": {
                "id": 541,
                "profileName": "FGFR4 G388R"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6301,
                    "pubMedId": 22034009,
                    "title": "Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22034009"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7293,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, germline FGFR G388R was associated with clinical response following neoadjuvant chemotherapy, and was associated with pathological complete response after treatment with Adria (doxorubicin) and Cytoxan (cyclophosphamide) followed by Taxotere (docetaxel) (AC-Doc) in breast cancer patients (PMID: 20147743).",
            "molecularProfile": {
                "id": 541,
                "profileName": "FGFR4 G388R"
            },
            "therapy": {
                "id": 1902,
                "therapyName": "Cyclophosphamide + Docetaxel + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6302,
                    "pubMedId": 20147743,
                    "title": "FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20147743"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 541,
            "profileName": "FGFR4 G388R",
            "profileTreatmentApproaches": [
                {
                    "id": 7562,
                    "name": "FGFR4 Inhibitor",
                    "profileName": "FGFR4 G388R"
                },
                {
                    "id": 7561,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR4 G388R"
                },
                {
                    "id": 9737,
                    "name": "STAT3 Inhibitor",
                    "profileName": "FGFR4 G388R"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 164518,
            "transcript": "NM_213647",
            "gDna": "chr5:g.177093242G>A",
            "cDna": "c.1162G>A",
            "protein": "p.G388R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 164519,
            "transcript": "NM_002011",
            "gDna": "chr5:g.177093242G>A",
            "cDna": "c.1162G>A",
            "protein": "p.G388R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 164520,
            "transcript": "XM_005265838",
            "gDna": "chr5:g.177093242G>A",
            "cDna": "c.1162G>A",
            "protein": "p.G388R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}